ALE.P02

PreclinicalSmall molecule

ALE.P02 is one of 5 small molecule programs targeting Squamous Non-small-cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Non-Small-Cell Lung CancerRecruiting

Squamous Non-Small-Cell Lung CancerPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Squamous Non-Small-Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Preclinical

1 2

Paraplatin

AAvyxa

Preclinical

1 3

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 4

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 5

ALE.P02

AAlentis Therapeutics AG

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Squamous Non-Small-Cell Lung Cancer

NCT06747585

Clinical

Trials by Indication[1]

Squamous Non-small-cell Lung Cancer1 trial

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

Recruiting·AAlentis Therapeutics AG·Preclinical·NCT06747585·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALE.P02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE.P02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE.P02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alentis Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlentis Therapeutics AG

ALE.P02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Squamous Non-small-cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News